Social customer relationship management (SCRM) services provider Tanma on Wednesday said it has closed its Series B round of financing, raising as much as $15 million.
The round was led by SoftBank Ventures Asia, an early-stage venture arm of Japanese SoftBank while existing investor Chinese Xiaomi’s Shunwei Capital also made a follow-on investment.
Tanma is targeting to invest the proceeds for software product innovation, market expansion and talent development.
The latest development comes two months after it secured $10 million in a Series A round from Legend Capital, Blue Lake Capital and K2VC in May this year.
Tanma claims to have served over 1,000 companies across sectors including education, finance, insurance, real estate and consumption.
CHINA DEAL MONITOR
DealStreetAsia has also put together a table listing out all prominent venture capital transactions in the Greater China region on July 27-28, 2021.
|Startup||Headquarter||Investment Size (USD)||Investment Stage||Lead Investor(s)||Other Investor(s)||Verticals|
|MicroPort Cardiac Rhythm Management Limited||Shanghai||150 million||C||Hillhouse Capital, MicroPort||CICC Capital, Country Garden Venture Capital, E Funds, Yongrong Asset, L Squared Private Management, Wanhui Capital||N/A|
|Joyo Pharma||Guangzhou||46 million||B||Sequoia Capital China, SDIC Venture Capital||LC Ventures, R Fund||N/A|
|Zion Pharma||Shanghai||40 million||B||OrbiMed Healthcare Fund Management||Qiming Venture Partners, Sherpa Healthcare Partners, Ming Bioventures, Medfine Capital||N/A|
|Lupeng Pharmaceutical||Guangzhou||35 million||Pre-B||Temasek||Lake Bleu Capital, Lilly Aisa Ventures, FC Capital||N/A|
|Dinfectome||Nanjing||30 million||-||IDG Capital||-||Biotech|
|Beijing Space Pioneer||Beijing||* 15 million||Pre-B||-||Zhangjianggang Shengtai Technology City, Jundu Investment, Zijin Investment||Infrastructure|
|YUSUR||Beijing||* 15 million||A||Huatai Investment||Lingjun Investment||AI and Machine Learning|
|iLabService||Shanghai||15 million||A||Matrix Partners China||-||Saas|
|3N Tech||Suzhou||15 million||A||Panlin Capital||Hainan Jinming Investment||N/A|
|Beisi Biotech||Zhuhai||15 million||Angel||-||Highlight Capital, Virtus Inspire Ventures, Panacea Venture, Hengqin Financial Investment|
|Tanma||Suzhou||15 million||B||SoftBank Ventures Asia||Shunwei Capital||Saas|
|Polly Polymer||Suzhou||15 million||A+||Vitalbridge||Infore Capital, Edge Venutes, Junzilan Capital, Dongyun Venture Capital, GSR Ventures||3D Printing|
|Z-Trip Business Management||Shanghai||* 10 million||B+||CITIC Capital||Dongfang Jiafu Investment, Unity Ventures, Zhang Tao (Individual Investor)||Saas|
|Hepa Thera Bio||Suzhou||4.6 million||Seed||-||Fosun Health Fund||N/A|
|Easy Power||Nanjing||-||A+||-||Addor Capital||AI and Machine Learning|
∗ indicates that the company did not provide the specific size of the deal but only a range. So, we adopt the smallest number in the range, which is “10 million yuan ($1.5 million)” in the given example.